AAC Accepts, published online ahead of print on 19 October 2009

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Rihakova, J. Articles by Drider, D. PubMed PubMed Citation Articles by Rihakova, J. Articles by Drider, D.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00765-09
Copyright (c) 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

In vivo activity of recombinant Divercin V41 and its structural variants against Listeria monocytogenes

Jitka Rihakova, Jean-Michel Cappelier, Isabelle Hue, Katerina Demnerova, Michel Fédérighi, Hervé Prévost, and Djamel Drider^*

UMR INRA SECALIM 1014 ENITIAA/ENVN. Rue de la Géraudière, BP 82225, 44322 Nantes Cedex, France; Department of Biochemistry and Microbiology, Institute of Chemical Technology, Technicka street 6, 166 28 Prague 6, Czech Republic; National Veterinary School of Nantes, La Chantrerie, BP 40706, 44307 Nantes Cedex, France

^* To whom correspondence should be addressed. Email: djamel.drider{at}enitiaa-nantes.fr.

Recombinant Divercin RV41 (DvnRV41) and its structural variants were used in this study to assess their antilisterial activities in vivo in mice challenged intravenously with Listeria monocytogenes EGDe. Treatment with DvnRV41 before and after infection permitted to conclude on capacity of this peptide to retain activity and reduce growth of L. monocytogenes. Moreover, the use of structural variants for first time in vivo and the drop of their activities confirmed the importance of certain amino-acids in the antilisterial activity.